Stocks and InvestingStocks and Investing
Wed, April 5, 2023
Tue, April 4, 2023
Mon, April 3, 2023
Sat, April 1, 2023
Fri, March 31, 2023

Judah Frommer Maintained (CADL) at Buy with Decreased Target to $7 on, Mar 31st, 2023


Published on 2024-10-28 02:31:40 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Candel Therapeutics, Inc." (CADL) at Buy with Decreased Target from $8 to $7 on, Mar 31st, 2023.

Judah has made no other calls on CADL in the last 4 months.



There is 1 other peer that has a rating on CADL. Out of the 1 peers that are also analyzing CADL, 0 agree with Judah's Rating of Hold.



This is the rating of the analyst that currently disagrees with Judah


  • Vernon Bernardino of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $11 on, Friday, December 2nd, 2022